BioNTech said in a disclosure today, Friday, that it had concluded two separate settlement agreements with the US National Institutes of Health and the University of Pennsylvania regarding the payment of fees for the use of intellectual property rights related to the “Covid-19” vaccine.
BioNTech – which is a partner of the giant American pharmaceutical company Pfizer in producing the anti-Covid-19 vaccine – added that it will pay $791.5 million to the American agency according to the agreement.
The German company has licensed some patents from the US National Institutes of Health, among others, making the US government eligible for some royalty payments.
Separately, BioNTech will pay $467 million to the University of Pennsylvania, which will dismiss a lawsuit filed against the company accusing it of not paying full royalties.
The University of Pennsylvania lawsuit says that BioNTech sublicensed the university’s technology through another company in 2017, which it later used to develop the “Comirnaty” vaccine with Pfizer.